Recombinant human luteinizing hormone (rhLH) + Recombinant follicle-stimulating hormone (rFSH)

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infertility

Conditions

Infertility, Ovulation Induction

Trial Timeline

Nov 1, 2008 → Oct 1, 2010

NCT ID

NCT01075815

About Recombinant human luteinizing hormone (rhLH) + Recombinant follicle-stimulating hormone (rFSH)

Recombinant human luteinizing hormone (rhLH) + Recombinant follicle-stimulating hormone (rFSH) is a phase 2 stage product being developed by Merck for Infertility. The current trial status is terminated. This product is registered under clinical trial identifier NCT01075815. Target conditions include Infertility, Ovulation Induction.

What happened to similar drugs?

10 of 20 similar drugs in Infertility were approved

Approved (10) Terminated (4) Active (10)

🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3

🔄Letrozole + Clomiphene citrateSun PharmaceuticalPhase 3

🔄Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)MerckPhase 3

✅Crinone + DuphastonMerckApproved

🔄hMG + Cetrorelix acetate + Coriogonadotropin alfa + Progesterone gelMerckPhase 3

✅FSHMerckApproved

🔄Pergoveris® + GONAL-f® + Recombinant human chorionic gonadotrophin (r-hCG)MerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01075815	Phase 2	Terminated	Nov 1, 2008	Oct 1, 2010	Infertility

Competing Products

20 competing products in Infertility

See all competitors

Product	Company	Stage	Hype Score
GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + Progesterone	Sun Pharmaceutical	Phase 3	40
Letrozole + Clomiphene citrate	Sun Pharmaceutical	Phase 3	40
Elagolix 200 MG + Leuprolide Acetate 3.75 MG/ML	AbbVie	Phase 1	29
Corifollitropin Alfa + Follitropin beta + oral contraceptive pill pretreatment (Marvelon)	Merck	Phase 3	40
Crinone + Duphaston	Merck	Approved	35
Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Pre-clinical	26
hMG + Cetrorelix acetate + Coriogonadotropin alfa + Progesterone gel	Merck	Phase 3	47
FSH	Merck	Approved	43
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)	Merck	Phase 1/2	32
Pergoveris® + GONAL-f® + Recombinant human chorionic gonadotrophin (r-hCG)	Merck	Phase 3	40
CFA + rFSH	Merck	Approved	43
Micronised Progesterone + Progesterone	Merck	Phase 3	40
AS900672-Enriched 50 microgram (mcg) + AS900672-Enriched 100 mcg + AS900672-Enriched 150 mcg + Follitropin alfa 150 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG)	Merck	Phase 2	35
gonadotropins plus GnRH antagonists + ganirelix	Merck	Pre-clinical	26
ELONVA + PUREGON	Merck	Pre-clinical	26
Gonalef® (Follitropin alfa) + Purified pituitary gonadotropin (Fertinorm-P®)	Merck	Phase 3	40
Estrogens	Merck	Phase 3	40
r-hFSH + r-hLH + u-hCG	Merck	Phase 2	35
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)	Merck	Phase 1/2	32
Gonal-f®	Merck	Approved	35